Philipp Knechtle Selected Research

Body Weight (Weight, Body)

1/2020

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philipp Knechtle Research Topics

Disease

5	Infections 10/2022 - 01/2019
4	Urinary Tract Infections (Urinary Tract Infection) 10/2022 - 01/2019
2	Pyelonephritis 10/2022 - 01/2020
2	Healthcare-Associated Pneumonia 12/2020 - 01/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2023
1	Cross Infection (Nosocomial Infection) 12/2020
1	Body Weight (Weight, Body) 01/2020
1	Pneumonia (Pneumonitis) 01/2020
1	Tinea (Ringworm) 01/2014
1	Trichophyton infection 01/2014

Drug/Important Bio-Agent (IBA)

7	Cefepime (Maxipime)FDA LinkGeneric 10/2022 - 01/2019
7	enmetazobactamIBA 10/2022 - 01/2019
2	LactamsIBA 10/2022 - 12/2020
2	Carbapenems (Carbapenem Antibiotics)IBA 01/2021 - 01/2019
1	Surface-Active Agents (Surfactants)IBA 01/2023
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 10/2022
1	beta-Lactamase InhibitorsIBA 01/2020
1	Tazobactam FDA LinkGeneric 01/2019
1	furanIBA 01/2014
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2014

Therapy/Procedure

1	Therapeutics 10/2022